Abstract
In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adam H. K., Gay M. A., Moore R. H. Measurement of tamoxifen in serum by thin-layer densitometry. J Endocrinol. 1980 Jan;84(1):35–42. doi: 10.1677/joe.0.0840035. [DOI] [PubMed] [Google Scholar]
- Adam H. K., Patterson J. S., Kemp J. V. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):761–764. [PubMed] [Google Scholar]
- Chemotherapy and tamoxifen for breast cancer. N Engl J Med. 1981 Oct 22;305(17):1014–1015. doi: 10.1056/NEJM198110223051713. [DOI] [PubMed] [Google Scholar]
- Glick J. H., Creech R. H., Torri S., Holroyde C., Brodovsky H., Catalano R. B., Varano M. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. Cancer. 1980 Feb 15;45(4):735–741. doi: 10.1002/1097-0142(19800215)45:4<735::aid-cncr2820450421>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- Hayward J. L., Rubens R. D., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A. Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer. 1978 Nov;14(11):1291–1292. doi: 10.1016/0014-2964(78)90238-4. [DOI] [PubMed] [Google Scholar]
- Henningsen B., Amberger H. Antiöstrogene Therapie des metastasierenden Mammakarzinoms. Vier Jahre Erfahrung mit Tamoxifen. Dtsch Med Wochenschr. 1977 May 13;102(19):713–716. doi: 10.1055/s-0028-1104958. [DOI] [PubMed] [Google Scholar]
- Lerner H. J., Band P. R., Israel L., Leung B. S. Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep. 1976 Oct;60(10):1431–1435. [PubMed] [Google Scholar]
- Manni A., Pearson O. H. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):779–785. [PubMed] [Google Scholar]
- Mouridsen H., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978 Sep;5(3):131–141. doi: 10.1016/s0305-7372(78)80017-6. [DOI] [PubMed] [Google Scholar]
- Stewart J. F., Minton M. J., Rubens R. D. Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily. Cancer Treat Rep. 1982 Jun;66(6):1445–1446. [PubMed] [Google Scholar]
- Ward H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973 Jan 6;1(5844):13–14. doi: 10.1136/bmj.1.5844.13. [DOI] [PMC free article] [PubMed] [Google Scholar]